NEONATAL RESPIRATORY DISTRESS SYNDROME TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Neonatal Respiratory Distress Syndrome Treatment Market - Drivers

The increasing prevalence of neonatal respiratory distress syndrome is expected to facilitate the market growth. According to the U.S National Library of Medicine, in 2015, neonatal respiratory distress syndrome was found in 6 to 7% neonates in the U.S. Therefore, there is potential opportunity for pharmaceutical companies to expand their presence in the neonatal respiratory distress syndrome treatment market. Thus, pharmaceutical companies are focusing on mergers and acquisitions to achieve growth and make profits in neonatal respiratory distress syndrome treatment market. For instance, in 2017, Aerogan Pharmaceuticals and Lyomark Pharmaceuticals merged with the aim of developing AP-002, a clinically superior treatment for neonatal respiratory distress syndrome. These factors are expected to drive the neonatal respiratory distress syndrome treatment market growth.

Neonatal Respiratory Distress Syndrome Treatment Market- Restraints.

Oxygen therapy and mechanical ventilation therapy is associated with common risk of pneumonia in neonates due to difficulty in breathing and coughing caused by breathing tube. In surfactant therapy, there is risk of bradycardia, hypoxemia during instillation in neonates. Moreover, the cost of neonatal ventilation is high and may be unaffordable for many patients in under developed countries such as India. These factors are expected to restrain global neonatal respiratory distress syndrome treatment market growth.